Centers For Medicare & Medicaid Services Issues ICD-10-PCS Codes For Humacyte's Human Acellular Vessel
Centers For Medicare & Medicaid Services Issues ICD-10-PCS Codes For Humacyte's Human Acellular Vessel
– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte's HAV –
從2024年10月1日起生效，使用Humacyte的HAV更換上肢和下肢動脈的ICD-10-PCS代碼有四種。
– BLA submission under Priority Review by FDA for the treatment of vascular trauma, supported by Phase 2/3 clinical trial results and real-world use treating wartime trauma injuries in Ukraine –
BLA提交受到FDA優先審查，用於治療血管創傷，在烏克蘭進行的二/三期臨床試驗結果和實際戰時創傷傷害的治療提供支持。
DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable, Human Acellular Vessels (HAVs) at commercial scale, today announced the issuance of four new ICD-10-PCS codes by the U.S. Centers for Medicare & Medicaid Services (CMS) ICD-10 Coordination and Maintenance (C&M) Committee. These codes, effective for hospital discharges beginning October 1, 2024, cover procedures for replacing arteries in the upper or lower extremities using Humacyte's HAV. Humacyte also announced that, based on guidance from the Food and Drug Administration (FDA), the common (non-brand) name for the HAV will be the "acellular tissue engineered vessel" (ATEV).
北卡羅來納州杜罕，2024年6月17日（環球新聞社）- Humacyte公司（NASDAQ:HUMA）是一家在進行規模化商業化開發全面植入的人類無細胞血管（HAVs）的臨床生物技術平台公司。今天，該公司宣佈，由美國醫療保險和醫療補助服務中心（CMS）ICD-10協調和維護（C＆M）委員會頒發了四項新的ICD-10-PCS代碼。這些代碼從2024年10月1日開始生效，用於涵蓋使用Humacyte的HAV更換上肢或下肢動脈的手術步驟。Humacyte還宣佈，根據FDA的指導意見，HAV的常見（非品牌）名稱將是“無細胞組織工程血管”（ATEV）。
譯文內容由第三人軟體翻譯。